AEON Biopharma IncAEON
Price$0.30

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$39.2MTTM through 31 Dec 2025
Free Cash Flow -$17.3MTTM through 31 Dec 2025

Margins

Current
Gross Margin0.0%

Returns

71.3%ROE
-70.5%ROA

Balance Sheet Health

Debt / Equity-0.63x
Current Ratio0.49x
Net Debt$31.6M
Cash & Equivalents$3M

Quality Metrics

Earnings-Beat Rate50.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
ABP-450 Biosimilar Development$00.0%
View details

Plans to complete the majority of the analytical comparability program in 2026 and request a BPD Type 2b FDA meeting in H2 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.